A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children

Trial Profile

A Pivotal Phase 3 Study of MEDI-524 (Numax; Motavizumab), an Enhanced Potency Humanized RSV Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2013

At a glance

  • Drugs Motavizumab (Primary) ; Palivizumab
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Jan 2010 Primary endpoint, relative reduction in respiratory syncytial virus hospitalisation, has been met.
    • 30 Jan 2010 Results will be published in 'Pediatrics'.
    • 08 May 2007 Results were presented at the Pediatric Academic Societies (PAS) annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top